tirzepatide loss of taste on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Physiological Integration of Taste and
Description
GLP-1 use is reshaping food consumption, driving demand for smaller portions, high-protein products, & packaging strategies.
95% CI 21.5 to 9.7)
Por qu los GLP 1 son un tratamiento de largo plazo
Phase 3 trials ongoing, NDA expected Q4 2026, approval late 2027-2028
Now add the biggest indication of all (~20 million clinically eligible Medicare patients over time)
